iCardiac Technologies

About iCardiac Technologies

iCardiac Technologies was acquired by ERT in December, 2017.

ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials so that our customers can move ahead with confidence. With nearly 50 years of clinical and therapeutic experience, we balance knowledge of what works with a vision for what’s next, so we can adapt without compromising standards.

Powered by the company’s EXPERT® technology platform, our solutions enhance trial oversight, enable site optimization, increase patient engagement, and measure the efficacy of new clinical treatments while ensuring patient safety. Over the past four years, more than half of all FDA drug approvals came from ERT-supported studies. Pharma companies, Biotechs, and CROs have relied on ERT solutions in over 10,000 studies spanning more than three million patients to date. By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly – and with confidence.

Follow ERT and learn how you can accelerate clinical development with confidence.

Website	http://www.ert.com
Employees	11-50 employees View all iCardiac Technologies employees
Industry	Biotechnology
Headquarter	1818 Market St, Philadelphia, Pennsylvania 19103, US
Founded	1997
Keywords	Consulting, Advanced Imaging, Respiratory Services, Spirometry, Cardiac Safety Services, Phase Ii-Iv Cardiac Safety, Phase I Qt Assessment, Tqt Studies, Centralized Trial Oversight, Electronic Clinical Outcome Assessments (Ecoa)